Profile data is unavailable for this security.
About the company
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
- Revenue in USD (TTM)0.00
- Net income in USD-888.60m
- Incorporated2022
- Employees256.00
- LocationBiohaven Ltd215 Church StreetNEW HAVEN 06510United StatesUSA
- Phone+1 (203) 404-0410
- Websitehttps://www.biohaven.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dynavax Technologies Corp | 294.62m | -60.07m | 1.23bn | 405.00 | -- | 2.39 | -- | 4.19 | -0.529 | -0.529 | 2.08 | 4.29 | 0.3049 | 0.7672 | 5.95 | 727,459.30 | -6.22 | 7.87 | -6.64 | 10.19 | 82.27 | 68.03 | -20.39 | 18.37 | 10.84 | -- | 0.3292 | 0.00 | 19.36 | 51.08 | 527.44 | -- | -26.39 | -- |
| Viridian Therapeutics Inc | 302.00k | -308.32m | 1.29bn | 143.00 | -- | 3.08 | -- | 4,272.54 | -4.24 | -4.24 | 0.0041 | 7.41 | 0.0005 | -- | -- | 2,111.89 | -47.75 | -50.26 | -50.07 | -53.97 | -- | -- | -102,092.40 | -12,930.56 | -- | -- | 0.0331 | -- | -3.82 | -41.64 | -13.55 | -- | 43.49 | -- |
| Travere Therapeutics Inc | 273.53m | -225.90m | 1.33bn | 385.00 | -- | 40.60 | -- | 4.87 | -2.79 | -2.80 | 3.35 | 0.3697 | 0.4513 | 2.58 | 9.58 | 710,475.30 | -37.27 | -41.64 | -52.74 | -51.97 | 96.01 | 95.90 | -82.59 | -175.36 | 2.03 | -- | 0.9204 | -- | 60.55 | 5.87 | 14.80 | -- | 45.42 | -- |
| Edgewise Therapeutics Inc | 0.00 | -146.09m | 1.37bn | 117.00 | -- | 2.89 | -- | -- | -1.55 | -1.55 | 0.00 | 4.51 | 0.00 | -- | -- | 0.00 | -28.98 | -26.21 | -30.04 | -27.42 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -33.60 | -- | 48.78 | -- |
| Janux Therapeutics Inc | 9.34m | -77.74m | 1.45bn | 74.00 | -- | 1.43 | -- | 154.97 | -1.36 | -1.36 | 0.164 | 17.11 | 0.0107 | -- | 3.06 | 126,162.20 | -8.94 | -13.75 | -9.08 | -14.23 | -- | -- | -832.71 | -743.21 | -- | -- | 0.00 | -- | 30.99 | -- | -18.36 | -- | -- | -- |
| Celldex Therapeutics Inc | 7.56m | -178.85m | 1.46bn | 186.00 | -- | 2.08 | -- | 193.24 | -2.70 | -2.70 | 0.1141 | 10.59 | 0.0094 | -- | 4.05 | 40,639.79 | -22.24 | -27.70 | -23.08 | -29.29 | -- | -- | -2,366.07 | -1,912.91 | -- | -- | 0.00 | -- | 1.99 | 14.46 | -11.62 | -- | 21.29 | -- |
| 89bio Inc | 0.00 | -386.67m | 1.48bn | 93.00 | -- | 2.45 | -- | -- | -3.38 | -3.38 | 0.00 | 4.15 | 0.00 | -- | -- | 0.00 | -61.26 | -51.66 | -65.19 | -55.58 | -- | -- | -- | -- | -- | -- | 0.056 | -- | -- | -- | -158.16 | -- | -35.94 | -- |
| Biohaven Ltd | 0.00 | -888.60m | 1.49bn | 256.00 | -- | 5.76 | -- | -- | -9.36 | -9.36 | 0.00 | 2.54 | 0.00 | -- | -- | 0.00 | -202.53 | -- | -283.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -107.37 | -- | -- | -- |
| Azenta Inc | 633.80m | -39.17m | 1.52bn | 3.00k | -- | 0.894 | 38.60 | 2.40 | -0.8323 | -1.41 | 13.19 | 37.17 | 0.2752 | 3.51 | 3.76 | 192,060.60 | -1.70 | -2.07 | -1.87 | -2.31 | 43.08 | 43.11 | -6.18 | -8.76 | 2.84 | -- | 0.00 | -- | -1.32 | -3.41 | -1,174.32 | -- | 9.40 | -- |
| Vera Therapeutics Inc | 0.00 | -175.46m | 1.53bn | 152.00 | -- | 2.86 | -- | -- | -2.99 | -2.99 | 0.00 | 8.39 | 0.00 | -- | -- | 0.00 | -34.09 | -54.55 | -35.34 | -60.06 | -- | -- | -- | -- | -- | -- | 0.0869 | -- | -- | -- | -58.50 | -- | 50.71 | -- |
| ARS Pharmaceuticals Inc | 97.12m | -15.65m | 1.62bn | 155.00 | -- | 7.08 | -- | 16.71 | -0.2536 | -0.2536 | 0.9449 | 2.33 | 0.35 | -- | 17.83 | 626,593.60 | -5.64 | -14.27 | -5.98 | -14.82 | 97.35 | -- | -16.11 | -224.85 | 10.74 | -- | 0.00 | -- | 297,063.30 | -- | 114.71 | -- | 42.45 | -- |
| Grail Inc | 130.71m | -1.91bn | 1.68bn | 1.00k | -- | 0.6832 | -- | 12.86 | -60.98 | -60.98 | 4.00 | 68.38 | 0.0383 | -- | 7.61 | 130,711.00 | -56.13 | -49.71 | -57.94 | -50.85 | 44.26 | 39.69 | -1,464.53 | -3,510.18 | -- | -- | 0.00 | -- | 34.90 | -- | -38.30 | -- | 9.34 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2025 | 8.21m | 8.12% |
| 1919 Investment Counsel LLCas of 31 Mar 2025 | 6.59m | 6.52% |
| Janus Henderson Investors US LLCas of 31 Mar 2025 | 6.34m | 6.27% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 6.32m | 6.25% |
| Suvretta Capital Management LLCas of 31 Mar 2025 | 5.62m | 5.56% |
| Farallon Capital Management LLCas of 31 Mar 2025 | 4.81m | 4.76% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 3.42m | 3.38% |
| RP Management LLC (Investment Management)as of 31 Mar 2025 | 2.94m | 2.90% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Mar 2025 | 2.74m | 2.71% |
| Bellevue Asset Management AGas of 31 Mar 2025 | 2.04m | 2.02% |
